Panic and anxiety: a decade of progress. Conference. Geneva (CHE), 1990/06.
Panic disorder is a chronic illness with only some degree of spontaneous recovery.
It is not surprising therefore that discontinuation of an effective medical treatment may be followed by relapse.
Therefore the timing and methodology of discontinuing that treatment are now recognized as essential facets of optimal clinical management.
In addition to relapse, rebound and the withdrawal syndrome have been reported with many psychotropic agents, particulary with the benzodiazepines.
This paper discusses data from three discontinuation studies with alprazolam i.e. the Phase I Cross-National Collaborative Panic discontinuation study after short-term treatment, the Phase I discontinuation study after long- term treatment, and data from the Montreal site of the Alprazolam SR discontinuation study.
Mots-clés Pascal : Panique, Trouble anxieux, Alprazolam, Benzodiazépine dérivé, Psychotrope, Efficacité traitement, Court terme, Long terme, Etude longitudinale, Arrêt traitement, Récidive, Sevrage syndrome, Epidémiologie, Enquête, Canada, Amérique du Nord, Amérique, Homme, Article synthèse
Mots-clés Pascal anglais : Panic, Anxiety disorder, Benzodiazepine derivatives, Psychotropic, Treatment efficiency, Short term, Long term, Follow up study, Withdrawal, Relapse, Withdrawal syndrome, Epidemiology, Inquiry, Canada, North America, America, Human, Review
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 94-0280731
Code Inist : 002B02B03. Création : 199406.